Raymond James analyst Andrew Cooper lowered the firm’s price target on Danaher (DHR) to $300 from $310 and keeps an Outperform rating on the shares. Danaher’s Q3 print kept with the trend of quarterly beats but included respiratory pull forward and saw guidance, and the tone for 2025 that left investors “somewhat underwhelmed,” the analyst says. The signs in bioprocessing, such as high single digit quarter over quarter order growth vs. a typical seasonal decline and a book:bill reaching 1x are positive and support the reiterated high single digit exit rate, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Danaher price target raised to $265 from $250 at Stifel
- Danaher price target raised to $315 from $310 at TD Cowen
- Danaher price target raised to $310 from $290 at KeyBanc
- Danaher price target lowered to $277 from $278 at Baird
- Danaher price target lowered to $275 from $285 at Barclays
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
